VIKING THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
After market 05:40:33 pm | |||
| 79.58 USD | +5.52% |
|
79.14 | -0.55% |
| Apr. 25 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
| Apr. 24 | Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 579.6 | 410.7 | 359.9 | 720.9 | 1,862 | 8,316 | - | - |
| Enterprise Value (EV) 1 | 303.9 | 162.3 | 157.8 | 565.4 | 1,499 | 7,422 | 7,567 | 7,520 |
| P/E ratio | -22.3 x | -10.4 x | -6.48 x | -10.4 x | -20.5 x | -67.4 x | -48.7 x | -44.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 218 x |
| EV / Revenue | - | - | - | - | - | - | - | 197 x |
| EV / EBITDA | -9.3 x | -3.81 x | -2.83 x | - | -14.9 x | -52.7 x | -43.3 x | -33.7 x |
| EV / FCF | -9.51 x | -7.45 x | -3.32 x | -11.7 x | -20.4 x | -68.8 x | -45.5 x | -35.4 x |
| FCF Yield | -10.5% | -13.4% | -30.2% | -8.56% | -4.89% | -1.45% | -2.2% | -2.83% |
| Price to Book | 2.08 x | 1.69 x | 1.78 x | 4.97 x | 5.35 x | 9.4 x | 11.3 x | - |
| Nbr of stocks (in thousands) | 72,264 | 72,952 | 78,235 | 76,688 | 100,029 | 110,268 | - | - |
| Reference price 2 | 8.020 | 5.630 | 4.600 | 9.400 | 18.61 | 75.42 | 75.42 | 75.42 |
| Announcement Date | 2/26/20 | 2/17/21 | 2/9/22 | 2/8/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 38.1 |
| EBITDA 1 | -32.69 | -42.66 | -55.68 | - | -100.8 | -140.8 | -174.8 | -223.5 |
| EBIT 1 | -32.69 | -42.66 | -55.68 | -70.36 | -100.8 | -143.6 | -188.6 | -196.2 |
| Operating Margin | - | - | - | - | - | - | - | -514.83% |
| Earnings before Tax (EBT) 1 | -25.78 | -39.5 | -54.99 | -68.87 | -85.9 | -120.4 | -170.6 | -184.4 |
| Net income 1 | -25.78 | -39.5 | -54.99 | -68.87 | -85.9 | -119.3 | -171.5 | -192.5 |
| Net margin | - | - | - | - | - | - | - | -505.25% |
| EPS 2 | -0.3600 | -0.5400 | -0.7100 | -0.9000 | -0.9100 | -1.118 | -1.549 | -1.698 |
| Free Cash Flow 1 | -31.96 | -21.78 | -47.59 | -48.4 | -73.38 | -107.9 | -166.2 | -212.5 |
| FCF margin | - | - | - | - | - | - | - | -557.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/17/21 | 2/9/22 | 2/8/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -12.51 | -16.24 | -17.63 | -16.2 | - | -20.54 | -23.74 | -27.26 | -29.28 | -34.07 | -33.66 | -35.55 | -37.48 | - | - |
| EBIT 1 | -12.51 | -16.24 | -17.63 | -16.2 | -20.28 | -20.54 | -23.74 | -27.26 | -29.28 | -34.07 | -35.11 | -36.56 | -37.85 | -48.17 | -52.68 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.36 | -16.1 | -17.43 | -15.77 | -19.56 | -19.53 | -19.22 | -22.53 | -24.6 | -27.36 | -29.18 | -30.83 | -32.28 | -38.77 | -43.54 |
| Net income 1 | -12.36 | -16.1 | -17.43 | -15.77 | -19.56 | -19.53 | -19.22 | -22.53 | -24.6 | -27.36 | -28.77 | -30.47 | -31.9 | -38.77 | -43.54 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1600 | -0.2100 | -0.2300 | -0.2100 | -0.2600 | -0.2500 | -0.1900 | -0.2300 | -0.2500 | -0.2600 | -0.2691 | -0.2827 | -0.2964 | -0.3133 | -0.3400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/9/22 | 4/27/22 | 7/27/22 | 10/26/22 | 2/8/23 | 4/26/23 | 7/26/23 | 10/25/23 | 2/7/24 | 4/24/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 276 | 248 | 202 | 155 | 362 | 895 | 749 | 796 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -32 | -21.8 | -47.6 | -48.4 | -73.4 | -108 | -166 | -212 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 3.850 | 3.340 | 2.580 | 1.890 | 3.480 | 8.020 | 6.650 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | 478 | 467 | 1.5 | 1.5 |
| Capex / Sales | - | - | - | - | - | - | - | 3.94% |
| Announcement Date | 2/26/20 | 2/17/21 | 2/9/22 | 2/8/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
75.42
USD
Average target price
108.4
USD
Spread / Average Target
+43.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +327.62% | 8.32B | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
- Stock Market
- Equities
- VKTX Stock
- Financials Viking Therapeutics, Inc.
